OncLive.com· @OncLive · X·· 22 小时前评分70
正文 · 原文
Adding pembrolizumab to adjuvant radiation did not improve 3-year RFS in newly diagnosed, early-stage, high-intermediate–risk, dMMR endometrial cancer #gynsm #oncology @myESMO #ESMO26
Read more: https://www.onclive.com/view/nrg-gy020-pembrolizumab-plus-radiation-fails-to-improve-rfs-in-dmmr-endometrial-cancer
170 浏览 · 3 赞 · 0 转发 · 0 回复
会议摘要
1239O按 Proffered paper: Gynaecological cancers 对上
NRG-GY020: Phase III randomized trial of radiation +/- MK-3475 (pembrolizumab) for newly diagnosed early-stage high intermediate risk (HIR) mismatch repair deficient (dMMR) endometrioid endometrial cancer
https://esmocongress.esmo.org来源：OncLive.com · x.com